We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Test Developed Using AI Proves Almost 100% Accurate in Detecting  COVID-19 Antibodies

By LabMedica International staff writers
Posted on 13 Dec 2021
Print article
Illustration
Illustration

A new test developed using AI-assisted technology has proven to be almost 100% accurate in detecting COVID antibodies.  

The Universal EpitoGen SARS-Cov-2-test developed by scientists at the University of Aberdeen (Aberdeen, Scotland) passed the penultimate round of quality assurance assessments by the NIBSC with a reported accuracy that would outperform existing COVID tests. In the NIBSC assessment, the Universal EpitoGen test detected antibody responses to infection by SARS-CoV-2 virus from patient samples with more than 99.5% accuracy and 98.5% specificity.

Unlike the ‘traditional,’ currently used tests, that can become less accurate as new variants emerge, the innovative EpitoGen technology is just as effective in detecting an antibody response to new variants without losing accuracy. Therefore, the new tests can be used to estimate the prevalence of circulating variant strains in the community, including the Omicron variant.

The Universal EpitoGen test was developed using innovative AI antibody technology known as EpitoGen and is one of a suite of tests currently in development. These include tests that can also assess the effectiveness of vaccines against new mutations and allows the incorporation of new mutations into existing tests in a matter of days - something that is not possible using the current technology.

“The news that our tests are so remarkably accurate is extremely exciting, particularly given the increasing worry around the emergence of new variants,” said Professor Mirela Delibegovic from the University of Aberdeen and academic lead on the project. “These tests can be adapted quickly and efficiently to incorporate new mutations - an important development, as we are right now realizing the importance of detecting and monitoring new COVID variants. So, to have the validation that this test has such a phenomenal level of accuracy is hugely encouraging and important.”

Related Links:
University of Aberdeen 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.